Reported Earnings • May 22
Third quarter 2026 earnings released: EPS: RM0.001 (vs RM0 in 3Q 2025) Third quarter 2026 results: EPS: RM0.001 (up from RM0 in 3Q 2025). Revenue: RM91.0m (up 1.3% from 3Q 2025). Net income: RM1.76m (up RM2.56m from 3Q 2025). Profit margin: 1.9% (up from net loss in 3Q 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • Feb 10
Second quarter 2026 earnings released: EPS: RM0.004 (vs RM0.001 loss in 2Q 2025) Second quarter 2026 results: EPS: RM0.004 (up from RM0.001 loss in 2Q 2025). Revenue: RM104.9m (up 30% from 2Q 2025). Net income: RM6.56m (up RM7.51m from 2Q 2025). Profit margin: 6.3% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 23
First quarter 2026 earnings released: EPS: RM0.003 (vs RM0.002 in 1Q 2025) First quarter 2026 results: EPS: RM0.003 (up from RM0.002 in 1Q 2025). Revenue: RM102.3m (up 25% from 1Q 2025). Net income: RM4.41m (up 50% from 1Q 2025). Profit margin: 4.3% (up from 3.6% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. New Risk • Nov 22
New major risk - Revenue and earnings growth Earnings have declined by 5.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.5% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (1.0% net profit margin). Announcement • Oct 27
TMC Life Sciences Berhad Approves Final Single-Tier Dividend Final Single-Tier Dividend in Respect of the Financial Year Ended 30 June 2025 TMC Life Sciences Berhad at its AGM held on October 27, 2025, approved the declaration and payment of a final single-tier dividend of 0.1863 sen per ordinary share in respect of the financial year ended 30 June 2025. Declared Dividend • Aug 28
Dividend reduced to RM0.0019 Dividend of RM0.0019 is 92% lower than last year. Ex-date: 8th December 2025 Payment date: 6th January 2026 Dividend yield will be 0.4%, which is lower than the industry average of 1.3%. Announcement • Aug 27
TMC Life Sciences Berhad announces Annual dividend, payable on January 06, 2026 TMC Life Sciences Berhad announced Annual dividend of MYR 0.0019 per share payable on January 06, 2026, ex-date on December 08, 2025 and record date on December 09, 2025. Reported Earnings • Aug 27
Full year 2025 earnings released: EPS: RM0.002 (vs RM0.023 in FY 2024) Full year 2025 results: EPS: RM0.002 (down from RM0.023 in FY 2024). Revenue: RM345.6m (flat on FY 2024). Net income: RM3.61m (down 91% from FY 2024). Profit margin: 1.0% (down from 12% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • May 22
Third quarter 2025 earnings released: EPS: RM0 (vs RM0.006 in 3Q 2024) Third quarter 2025 results: EPS: RM0 (down from RM0.006 in 3Q 2024). Revenue: RM91.1m (up 5.9% from 3Q 2024). Net loss: RM806.0k (down 108% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Apr 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 29% to RM0.37. The fair value is estimated to be RM0.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 3.3%. Reported Earnings • Feb 11
Second quarter 2025 earnings released: EPS: RM0 (vs RM0.008 in 2Q 2024) Second quarter 2025 results: EPS: RM0 (down from RM0.008 in 2Q 2024). Revenue: RM81.5m (down 13% from 2Q 2024). Net loss: RM947.0k (down 107% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Upcoming Dividend • Nov 28
Upcoming dividend of RM0.022 per share Eligible shareholders must have bought the stock before 05 December 2024. Payment date: 03 January 2025. Payout ratio is a comfortable 30% but the company is paying out more than the cash it is generating. Trailing yield: 4.4%. Lower than top quartile of Malaysian dividend payers (4.9%). Higher than average of industry peers (1.4%). Announcement • Nov 21
Tmc Life Sciences Berhad Removes Wan Nadiah Binti Wan Mohd Abdullah Yaakob as A Director TMC Life Sciences Berhad announced that Wan Nadiah Binti Wan Mohd Abdullah Yaakob (NRIC No. 840417-14-5216) be removed as a director of the Company with immediate effect. Reported Earnings • Nov 19
First quarter 2025 earnings released: EPS: RM0.002 (vs RM0.009 in 1Q 2024) First quarter 2025 results: EPS: RM0.002 (down from RM0.009 in 1Q 2024). Revenue: RM82.8m (down 10% from 1Q 2024). Net income: RM2.94m (down 81% from 1Q 2024). Profit margin: 3.5% (down from 16% in 1Q 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Oct 07
TMC Life Sciences Berhad, Annual General Meeting, Nov 06, 2024 TMC Life Sciences Berhad, Annual General Meeting, Nov 06, 2024, at 10:00 Singapore Standard Time. Location: emerald & garnet room, level g, avantehotel, no. 1, persiaran bandar utama, bandar utama, 47800 petaling jaya, selangor darul ehsan, Malaysia New Risk • Aug 25
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Declared Dividend • Aug 23
Dividend of RM0.022 announced Shareholders will receive a dividend of RM0.022. Ex-date: 5th December 2024 Payment date: 3rd January 2025 Dividend yield will be 3.8%, which is higher than the industry average of 1.3%. Payout Ratios Payout ratio: 14%. Cash payout ratio: 16%. Reported Earnings • Aug 22
Full year 2024 earnings released: EPS: RM0.023 (vs RM0.023 in FY 2023) Full year 2024 results: EPS: RM0.023 (in line with FY 2023). Revenue: RM346.4m (up 11% from FY 2023). Net income: RM40.6m (up 3.5% from FY 2023). Profit margin: 12% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • May 24
Third quarter 2024 earnings released: EPS: RM0.006 (vs RM0.008 in 3Q 2023) Third quarter 2024 results: EPS: RM0.006 (down from RM0.008 in 3Q 2023). Revenue: RM86.9m (up 6.5% from 3Q 2023). Net income: RM9.96m (down 30% from 3Q 2023). Profit margin: 12% (down from 18% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 03
Second quarter 2024 earnings released: EPS: RM0.008 (vs RM0.003 in 2Q 2023) Second quarter 2024 results: EPS: RM0.008 (up from RM0.003 in 2Q 2023). Revenue: RM94.8m (up 29% from 2Q 2023). Net income: RM14.5m (up 165% from 2Q 2023). Profit margin: 15% (up from 7.5% in 2Q 2023). The increase in margin was driven by higher revenue. Announcement • Jan 29
TMC Life Sciences Berhad Announces Redesignation of Dr Heng Jun Li Melvin from Non Executive Director to Group Chief Executive Officer TMC Life Sciences Berhad announced redesignation of Dr Heng Jun Li Melvin from previous position Non Executive Director to new position Group Chief Executive Officer, Directorate is Executive. Age is 41, gender is Male and nationality is Singapore. Date of change is 29 January 2024. Qualifications: Masters of Business Administration from Frankfurt School of Finance & Management; Bachelor of Medicine and Bachelor of Surgery (MBBS) from University of London, St Georges Hospital; Graduate Diploma Occupational Medicine from National University of Singapore. Working experience and occupation: Thomson Medical Group Limited, Singapore 1 December 2022 to present Executive Director and Group Chief Executive Officer; Gleneagles Hospital, IHH Healthcare January 2021 to 31 October 2022 Chief Executive Officer; July 2019 to December 2020 Chief Operating Officer September 2017 to June 2019 AVP, Operations; Mesh Bio Pte Ltd. July 2018 to Present Co-Founder & Medical Advisor; Ministry of Health, Singapore August 2016 to January 2018 Medical Advisor; Global Health Byte Holdings Pte Ltd. (UNO Technologies Pte Ltd) June 2016 to December 2018 Investor & Medical Advisor; OneCare Medical Pte Ltd. August 2014 to September 2017 Equity Partner; Global Medical Concierge Pte Ltd. January 2013 to June 2017 Co-Founder; Tan Tock Seng Hospital January 2013 to March 2015 Medical Doctor, Radiology; National Health Service (United Kingdom) June 2009 to August 2011 Medical Doctor. Dr Heng Jun Li Melvin will assume the role of Acting Group Chief Executive Officer of the Company on 29 January 2024. Reported Earnings • Nov 16
First quarter 2024 earnings released: EPS: RM0.009 (vs RM0.004 in 1Q 2023) First quarter 2024 results: EPS: RM0.009 (up from RM0.004 in 1Q 2023). Revenue: RM93.9m (up 31% from 1Q 2023). Net income: RM15.1m (up 143% from 1Q 2023). Profit margin: 16% (up from 8.7% in 1Q 2023). The increase in margin was driven by higher revenue. Announcement • Oct 05
TMC Life Sciences Berhad, Annual General Meeting, Nov 02, 2023 TMC Life Sciences Berhad, Annual General Meeting, Nov 02, 2023. Location: Emerald & Garnet Room, Level G, AVANTÉ Hotel,No. 1, Persiaran Bandar Utama, Bandar Utama, 47800 Petaling Jaya, Selangor Darul Ehsan Selengor Malaysia Agenda: To receive the Audited Financial Statements for the financial year ended 30 June 2023 together with the Reports of the Directors and the Auditors thereon; To approve the declaration and payment of a final single-tier dividend of 0.4199 sen per ordinary share in respect of the financial year ended 30 June 2023; To approve the declaration and payment of a special single-tier dividend of 0.4199 sen per ordinary share in respect of the financial year ended 30 June 2023. Reported Earnings • Aug 23
Full year 2023 earnings released: EPS: RM0.023 (vs RM0.024 in FY 2022) Full year 2023 results: EPS: RM0.023 (down from RM0.024 in FY 2022). Revenue: RM311.4m (up 28% from FY 2022). Net income: RM39.3m (down 5.2% from FY 2022). Profit margin: 13% (down from 17% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Board Change • Aug 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent & Non Executive Director Mohd bin Ramli was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 24
Third quarter 2023 earnings released: EPS: RM0.008 (vs RM0.004 in 3Q 2022) Third quarter 2023 results: EPS: RM0.008 (up from RM0.004 in 3Q 2022). Revenue: RM83.3m (up 36% from 3Q 2022). Net income: RM14.3m (up 105% from 3Q 2022). Profit margin: 17% (up from 11% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • May 20
TMC Life Sciences Berhad Announces Appointment of Puan Mazrina Binti Arifin as Independent and Non Executive Director TMC Life Sciences Berhad announced appointment of Puan Mazrina Binti Arifin as Independent and Non Executive Director. Age 54, Date of change 19 May 2023. Qualifications: Professional Qualification-Certified Chartered Accountant-Chartered Association of Certified Accountants in England, Degree-Bachelor of Science in Accounting-University of Hull, United Kingdom. Working experience: Ms. Mazrina binti Arifin ("Ms. Mazrina") was attached to Arthur Andersen Tax Services Sdn. Bhd. from 1995 to 1998 and was a Senior Tax Consultant prior to her leaving the firm. She was the Founder and Managing Director of Under6ers, Child Enrichment Centres, in Kuala Lumpur and Selangor from 2001 to 2009. Ms. Mazrina was appointed as Finance Director for Springboard4 Malaysia Sdn. Bhd. and Springboard 4 Asia Ltd. (Labuan) from 2010 to 2015. Ms. Mazrina was appointed as Finance Director of the Institute for Democracy and Economic Affairs (IDEAS) Berhad, IDEAS Autism Centre (Special Project) and IDEAS Research and Policy Berhad from 2015 to present. Ms. Mazrina was a Senior Independent Non-Executive Director of Hup Seng Industries Berhad from 2000 to 2022. Reported Earnings • Feb 09
Second quarter 2023 earnings released: EPS: RM0.003 (vs RM0.004 in 2Q 2022) Second quarter 2023 results: EPS: RM0.003 (down from RM0.004 in 2Q 2022). Revenue: RM73.3m (up 24% from 2Q 2022). Net income: RM5.49m (down 21% from 2Q 2022). Profit margin: 7.5% (down from 12% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Jan 27
TMC Life Sciences Berhad Appoints Dr. Heng Jun Li Melvin as Non Independent and Non Executive Director TMC Life Sciences Berhad appointed Dr. Heng Jun Li Melvin, 40-year-old, as Non Independent and Non Executive Director with effect from January 26, 2023. Qualifications: Masters of Business Administration from Frankfurt School of Finance & Management; Bachelor of Medicine and Bachelor of Surgery ("MBBS") from University of London, St Georges Hospital; and Graduate Diploma Occupational Medicine from National University of Singapore. Working experience and occupation: Gleneagles Hospital, IHH Healthcare January 2021 to 31 October 2022 Chief Executive Officer; July 2019 to December 2020: Chief Operating Officer; September 2017 to June 2019: AVP, Operations; Mesh Bio Pte Ltd: July 2018 to Present: Co-Founder & Medical Advisor; Ministry of Health, Singapore: August 2016 to January 2018 as Medical Advisor; Global Health Byte Holdings Pte Ltd. (UNO Technologies Pte Ltd) June 2016 to December 2018 as Investor & Medical Advisor; OneCare Medical Pte Ltd: August 2014 to September 2017 as Equity Partner; Global Medical Concierge Pte Ltd. January 2013 to June 2017 as Co-Founder; Tan Tock Seng Hospital January 2013 to March 2015 as Medical Doctor, Radiology; National Health Service (United Kingdom) June 2009 to August 2011 as Medical Doctor. Announcement • Nov 17
TMC Life Sciences Berhad Reports Write Offs for the Quarter Ended September 30, 2022 TMC Life Sciences Berhad reported write offs for the quarter ended September 30, 2022. for the quarter, the company reported Property, plant and equipment written off of MYR 12,000. Reported Earnings • Nov 17
First quarter 2023 earnings released: EPS: RM0.004 (vs RM0.002 in 1Q 2022) First quarter 2023 results: EPS: RM0.004 (up from RM0.002 in 1Q 2022). Revenue: RM72.6m (up 38% from 1Q 2022). Net income: RM6.23m (up 54% from 1Q 2022). Profit margin: 8.6% (up from 7.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Oct 06
TMC Life Sciences Berhad, Annual General Meeting, Nov 03, 2022 TMC Life Sciences Berhad, Annual General Meeting, Nov 03, 2022, at 10:00 Singapore Standard Time. Agenda: To receive the Audited Financial Statements for the financial year ended 30 June 2022 together with the Reports of the Directors and the Auditors thereon; to approve the declaration and payment of a final single-tier dividend of 0.2763 sen per ordinary share in respect of the financial year ended 30 June 2022; to approve the payment of Directors' fees amounting to RM650,000 for the financial year ending 30 June 2024; to approve the payment of Directors' benefits amounting to RM200,000 for the financial year ending 30 June 2024; and to consider other matters. Reported Earnings • Aug 26
Full year 2022 earnings released: EPS: RM0.024 (vs RM0.012 in FY 2021) Full year 2022 results: EPS: RM0.024 (up from RM0.012 in FY 2021). Revenue: RM243.8m (up 21% from FY 2021). Net income: RM41.4m (up 104% from FY 2021). Profit margin: 17% (up from 10% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Aug 24
TMC Life Sciences Berhad Proposes Single-Tier Final Dividend for the Financial Year Ended 30 June 2022, Payable on 03 January 2023 TMC Life Sciences Berhad proposed a single-tier final dividend of 0.2763 sen per ordinary share for the financial year ended 30 June 2022 subject to the shareholders' approval at the forthcoming Twentieth Annual General Meeting of the Company. Ex-date is 05 December 2022; Entitlement date is 06 December 2022 and Payment date is 03 January 2023. Reported Earnings • May 28
Third quarter 2022 earnings released: EPS: RM0.004 (vs RM0.002 in 3Q 2021) Third quarter 2022 results: EPS: RM0.004 (up from RM0.002 in 3Q 2021). Revenue: RM61.6m (up 16% from 3Q 2021). Net income: RM6.97m (up 86% from 3Q 2021). Profit margin: 11% (up from 7.0% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year and the company’s share price has also fallen by 10% per year. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Alternate Director Wilson Sam was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Alternate Director Wilson Sam was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Alternate Director Wilson Sam was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Feb 17
TMC Life Sciences Berhad Announces Re-Designation of Wong Yu Chee as Group Chief Accounting Officer from Group Chief Financial Officer TMC Life Sciences Berhad announced Re-designation of Mr. Wong Yu Chee as Group Chief Accounting Officer from Group Chief Financial Officer of the company, with effect from February 16, 2022.